EASL 2019 Conference Review, reviewed by A/Prof William Kemp

In this review:

Obeticholic acid for NASH
Sofosbuvir/velpatasvir/voxilaprevir salvage in chronic HCV
Enriched FMT for recurrent hepatic encephalopathy
Sofosbuvir/velpatasvir for chronic HCV
Glecaprevir/pibrentasvir for HCV
Ramucirumab for advanced HCC and elevated alpha-fetoprotein
Neutrophil-to-lymphocyte ratio in alcoholic hepatitis
Predicting HCC risk after HCV treatment
Short-term RNA interference therapy in chronic HBV
Tenofovir vs entecavir in chronic HBV
Myrcludex B plus pegylated interferon α-2a for chronic HBV/HDV coinfection
Endoscopy timing and variceal bleeding mortality

Please login below to download this issue (PDF)